Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 1/20 | 0.37 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | CDK7 | P50613 | 1/20 | 0.35 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.35 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.35 |
| ▸ | GRM1 | Q13255 | 9/20 | 0.35 |
| ▸ | GRM5 | P41594 | 8/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | KIT | P10721 | 1/20 | 0.34 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21157311 | 0.86 | EED (0.39) | SOS1PDK4NAMPTCDK7CDK13 | |
| SCHEMBL21156537 | 0.84 | ALDH1A1 (0.34) | SMN1; SMN2 | |
| SCHEMBL21113284 | 0.80 | RET (0.44) | — | |
| SCHEMBL21157283 | 0.78 | ALOX15 (0.41) | SMN1; SMN2 | |
| SCHEMBL21113386 | 0.78 | TBK1 (0.41) | — | |
| SCHEMBL21113279 | 0.78 | NAMPT (0.41) | PDK4NAMPTGRM1GRM5CYP11B2 | |
| SCHEMBL21157291 | 0.77 | EED (0.43) | USP2SMN1; SMN2 | |
| SCHEMBL21156531 | 0.77 | ALDH1A1 (0.40) | USP2SMN1; SMN2 | |
| SCHEMBL21156563 | 0.77 | ALDH1A1 (0.35) | SMN1; SMN2 | |
| SCHEMBL21113181 | 0.77 | LMNA (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10968215-B2 | Pyrido five-element aromatic ring compound, preparation method therefor and use thereof | SHANGHAI HAIHE PHARMACEUTICAL CO., LTD. (CN) | 2021-04-06 | — | — | US | disclosed |
| US-20190211010-A1 | PYRIDO FIVE-ELEMENT AROMATIC RING COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | HAIHE BIOPHARMA CO. LTD. (CN) | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10968215-B2 | Pyrido five-element aromatic ring compound, preparation method therefor and use thereof | EZH2, IKZF2, SUZ12 | SOS1 430/4885PDK4 938/4885NAMPT 947/4885 |
| US-20190211010-A1 | PYRIDO FIVE-ELEMENT AROMATIC RING COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | EZH2, IKZF2, SUZ12 | SOS1 430/4885PDK4 938/4885NAMPT 947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.